Stage IV Lung Cancer AJCC v8 Clinical Trials in Seattle, Washington

10 studies are recruiting for stage iv lung cancer ajcc v8 in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

   This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell sign…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Pacific Gynecology Specialists, Seattle, Washington

   Locations

   603 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04181060 on ClinicalTrials.gov

2. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

   This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

   Stage

   Phase 3

   Ages

   70 and older

   Site

   Swedish Medical Center-First Hill, Seattle, Washington

   Locations

   324 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06096844 on ClinicalTrials.gov

3. SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

   This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary si…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT07322341 on ClinicalTrials.gov

4. Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

   This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients with breast cancer or non-small cell lung cancer (NSCLC) that has spread from the original (primary) t…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Locations

   3 in total

   Run by

   University of Washington

   See if you can join NCT06518057 on ClinicalTrials.gov

5. PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

   This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer. Analyzing changes in PET/CT imaging scans may help doctors assess and pred…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT04151940 on ClinicalTrials.gov

6. A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

   This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonuclei…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Locations

   2 in total

   Run by

   University of Washington

   See if you can join NCT05242965 on ClinicalTrials.gov

7. Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

   This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or does not r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT05098210 on ClinicalTrials.gov

8. SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

   This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent). SX-682 is a drug that binds to receptors on some…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT05570825 on ClinicalTrials.gov

9. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

   This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) an…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   454 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05642572 on ClinicalTrials.gov

10. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period o…

    Stage

    Phase 2

    Ages

    Any age

    Site

    Swedish Medical Center-First Hill, Seattle, Washington

    Locations

    266 in total

    Run by

    SWOG Cancer Research Network

    See if you can join NCT06031688 on ClinicalTrials.gov